research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
Search
for
Sort by
Research
150-180 / 1000+ results 
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China
Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research Janus kinase (JAK)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Ku80 as a Novel Receptor for Thymosin β4 That Mediates Its Intracellular Activity Different from G-actin Sequestering
Ku80 is a key receptor for Thymosin β4, affecting cell migration and wound healing.
research Turning JAK STATic, a peek into the future of dermatology therapeutics
JAK inhibitors show promise for treating skin diseases effectively and safely.
research Topical Application of a Protein Kinase C Inhibitor Reduces Skin and Hair Pigmentation
Applying a specific inhibitor lightens skin and hair color.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
research Experimental and Finite Element Analysis of a Residual Hair Keratin‐based Hydrogel with Calcium for Atorvastatin Sequestration, Release, and In Vitro Activity
Keratin-based hydrogels with calcium are effective for delivering anti-fibrotic drugs.
research Janus kinase inhibitors in dermatology: A systematic review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
JAK inhibitors can enter the skin through hair follicles using a unique pathway.
research Janus kinase inhibitors: An innovative treatment for alopecia areata
New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
research 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
research Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research K15 promoter-driven enforced expression of NKIRAS exhibits tumor suppressive activity against the development of DMBA/TPA-induced skin tumors
NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.